Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Faheem Hasnain
AddedFeb 13, 2024
UpdatedMay 31, 2026
Faheem Hasnain

Faheem Hasnain

Board Member, Sente

CrunchbaseLinkedInThe Org

Faheem Hasnain's Career

Sente
Sente

Carlsbad, CA, US

Board Member· Board
Aspen Neuroscience
Aspen Neuroscience

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Faheem Hasnain's Career

Sente
Sente
Series A$17.9M492007Carlsbad, CA, US
Board Member· Board

Leadership at Sente

Laurent CombredetLaurent CombredetCEO
Clint CarnellClint CarnellBoard Member
Kleanthis G. XanthopoulosKleanthis G. XanthopoulosBoard Member
Magda MarquetMagda MarquetBoard Member

Similar to Sente

Enhance Skin ProductsEnhance Skin ProductsDenver, CO, USCosmetics, Skincareest. 2006Enhance Skin ProductsDenver, CO, US · est. 2006

Enhance Skin Products, Inc.: Premium provider of branded cosmeceuticals that biologically enhance skin.

Public6
StratiaStratiaBoston, MA, USCosmetics, Skincareest. 2016StratiaBoston, MA, US · est. 2016

Stratia: Your online destination for premium skincare products.

Seed · $2M8
CurologyCurologySan Francisco, CA, USSkincareest. 2014CurologySan Francisco, CA, US · est. 2014

Curology offers personalized prescription skincare, targeting acne and anti-aging, delivered to your door.

Series B · $19.1M750
FutureDermFutureDermPittsburgh, PA, USProducts, Skincareest. 2012FutureDermPittsburgh, PA, US · est. 2012

FutureDerm: Your global online hub for science-backed skincare insights and products.

Angel · $682.8k5
Aspen Neuroscience
Aspen Neuroscience
Series D$264M1122018San Diego, CA, US
Board Member· Board

Leadership at Aspen Neuroscience

Doug FisherDoug FisherBoard Member
Caryn PetersonCaryn PetersonBoard Member
Jeanne LoringJeanne LoringCo-Founder
Drew SpaventaDrew SpaventaBoard Member
Peter ThompsonPeter ThompsonBoard Member
Andrés Bratt-LealAndrés Bratt-LealCo-Founder

Similar to Aspen Neuroscience

ConvalesceConvalesceSan Francisco, CA, USStem Cell Therapyest. 2018ConvalesceSan Francisco, CA, US · est. 2018

Convalesce: Pioneering stem cell therapies for neurodegenerative conditions using advanced biomaterials.

Angel · $250k3
APstem TherapeuticsAPstem TherapeuticsFremont, CA, USStem Cell Therapiesest. 2017APstem TherapeuticsFremont, CA, US · est. 2017

APstem Therapeutics: Advancing stem cell discoveries to combat diseases and aging challenges.

Seed · $4.3M6
NeuronascentNeuronascentClarksville, MD, USTherapeuticsest. 2004NeuronascentClarksville, MD, US · est. 2004

US-based Neuronascent develops pioneering therapeutics for neurodegenerative diseases and depression.

Pre-Seed · $1.3M5
Personalized Stem CellsPersonalized Stem CellsPoway, CA, USStem Cell Servicesest. 2018Personalized Stem CellsPoway, CA, US · est. 2018

Personalized Stem Cells offers FDA-approved, adipose-derived stem cell services for clinical trials.

Seed · $2.4M2

Faheem Hasnain's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Faheem Hasnain

Akshay NanduriAkshay NanduriCo-Founder · Onc.AIAlexander PolinskyAlexander PolinskyCo-Founder · OncoTartisMichael ChoukasMichael ChoukasCo-Founder · Autem TherapeuticsOfer SharonOfer SharonCo-Founder · Valera HealthPatrick TreacyPatrick TreacyCo-Founder · Onkos SurgicalMike MorrisseyMike MorrisseyCEO · Exelixis